Acurx Pharmaceuticals, Inc.
ACXP · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $5,404 | $6,044 | $4,754 | $2,030 |
| G&A Expenses | $8,699 | $8,534 | $7,339 | $10,784 |
| SG&A Expenses | $8,699 | $8,534 | $7,339 | $10,784 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $14,103 | $14,578 | $12,093 | $12,814 |
| Operating Income | -$14,103 | -$14,578 | -$12,093 | -$12,814 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | $0 | $0 | $67 |
| Pre-Tax Income | -$14,103 | -$14,578 | -$12,093 | -$12,748 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$14,103 | -$14,578 | -$12,093 | -$12,748 |
| % Margin | – | – | – | – |
| EPS | -17.59 | -23.01 | -22.36 | -24.96 |
| % Growth | 23.6% | -2.9% | 10.4% | – |
| EPS Diluted | -17.59 | -23.01 | -22.36 | -24.96 |
| Weighted Avg Shares Out | 852 | 634 | 541 | 511 |
| Weighted Avg Shares Out Dil | 852 | 634 | 541 | 511 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $14,103 | $0 | $0 | $0 |
| EBITDA | $0 | -$14,578 | -$12,093 | -$12,814 |
| % Margin | – | – | – | – |